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ABSTRACT 
Objective: In this study, Myrica esculenta (ME) leaves extract along with Coenzyme Q10 was entrapped in nanostructured lipid carriers (NLCs). The 
formulation variables were successfully optimized using 23 factorial design. 
Methods: Preparation of NLC was carried out by solvent injection technique. The formulation of NLC was consisting of the methanolic extract of Myrica 
esculenta leaves and Coenzyme Q10 as key ingredients. Oleic Acid (OA) was taken as liquid lipid, Precirol ATO 5 (PATO) as solid lipid, and Poloxamer 
407 (P407). The formulation variables were statically optimized using 23 factorial design, followed by the characterization of the formulation. 
Results: The results demonstrated that the best optimized NLC formulation F5 of Coenzyme Q10 and plant extract exhibited the smallest size 
169.46 nm and highest entrapment efficiency 90.06±0.171 %. Furthermore, it showed good physical stability at 28 d after preparation.  
Conclusion: The developed NLCs of Q10-ME extract from this study could be explored as the effective anti-ageing formulation. 
Keywords: Anti-aging cosmetics, Antioxidant activity, Factorial design nanostructured lipid carriers 




The human being of the modern world had a great inclination to 
search for an everlasting youth. In this physical world facial 
appearance became a crucial factor to influence social relations in 
many situations due to which people tend to judge personality based 
on facial manifestation [1]. This desire had ultimately triggered for the 
development of new products, methods and technology in the 
cosmeceutical industry which might revert back the clock [2]. Skin is 
the largest human organ contributing, a major target of oxidative 
stress [3]. Skin aging is a gradual deterioration of the physiological 
functions of skin which results in wrinkles or loose skin that causes 
unattractive appearances. Several theories have been laid down to 
describe the mechanism of the skin aging of which the most successful 
and referred is the free radical theory based on oxidative stress [4].  
Many antioxidant agents have been studied to develop novel anti-
aging products. Coenzyme Q10 one of the most popular antioxidants, 
naturally occurring in the skin that had been studied in this field [5] 
most common products composed of CoQ10 generally contained in 
the range of 0.5–1.0% in anti-wrinkle products as well as in anti-
oxidant products. It is having the tendency to show the adverse 
effect at higher doses if taken orally [6]. 
To solve this problem lipid-based nano-particulate drug carriers 
have been developed to increase solubility and improve the 
bioavailability of poorly water soluble and/or lipophilic drugs [7]. 
The plant extracts usually contain polyphenols such as flavonoids, 
which react with reactive oxygen species (ROS) to neutralize the 
harmful effects of free radicals [8]. 
Myrica esculenta Buch.-Ham. (Myricaceae) commonly known as Box 
Berry, Kaiphal, and Katphala in Ayurveda is widely used treatment of 
gulma (abdominal tumors), jvara (fever), arsa (piles), grahani 
(irregular bowel function), pandu roga (anemia), hrillasa (nausea), 
mukha roga. The medicinal properties of M. Esculenta are well known 
as per ethnobotanical surveys. Therefore in present study researcher 
had made an attempt to develop topical drug delivery system which 
may enhance the potency of Coenzyme Q10 by incorporating 
methanolic extract of M. esculenta into NLC carriers to offer a great 
potential to justify the objectives of present work [9]. Considering 
these aspects, researchers have selected NLCs as carriers due to their 
special nanostructures which tend to improved properties for 
therapeutic loading, better drug release profile and stability [10].  
MATERIALS AND METHODS 
Coenzyme Q10 (CoQ10) was purchased from Sigma-Aldrich 
Chemicals, St. Louis, MO. Precirol ATO 5 (PATO), Oleic Acid (OA) and 
Poloxamer 407 (P407) were provided as gift samples from 
Gattefossé Saint-Priest, France and BASF Corporation, USA 
respectively. All other chemicals and reagents used were of 
analytical grade and procured from SD Fine Chem Limited, Mumbai. 
The plant specimen, i.e. dried leaves of M. esculenta were collected 
from the northern Himalayan region of Garhwal Uttarakhand, India 
in the month of March 2015 from the height of 1685.53 Meters N 
29.8688 ° N, 78.8383 ° E. The plants were identified and 
authenticated in BSI, Allahabad, India (voucher specimen BSA-
94627). The Standardization of plant extract was carried out 
through HPLC method followed by quantification of gallic acid in M. 
esculenta extract using RP-HPLC. The NLCs were prepared through 
the solvent injection technique and statically optimized by 23 
factorial design [11-12].  
Standardization of plant extract through HPLC method 
M. esculenta methanolic extract was standardized through reverse-
phase high-performance liquid chromatography (RP-HPLC). 
Lyophilized hydro-alcoholic extract of M. esculenta was accurately 
weighted and volume of the solution was adjusted in a volumetric 
flask to obtain a final concentration of 1 mg/ml. The optimized 
mobile phase consisted of acetone with 1% acetic acid in water in 
the ratio of 76: 24 (v/v) with the flow rate of 1 ml/min. The HPLC 
system comprised of rheodyne-7725 injection valve with a sample 
loop (20 ml), Vacuum degasser, quaternary pump and photo-diode 
array detector (PDA) was used, with data acquisition by Empower 
TM 2 software (Waters 600, Milford, MA, USA). Chromatography was 
performed on a Spherisorb C18 column (250 mm × 4.6 mm, 5 mm; 
Waters, Ireland) fitted with a C18 guard column (10 × 3.0 mm). The 
sample elution was performed at 25 °C and detected at the UV 
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wavelength of 254 nm. A sample was analyzed by HPLC using 20μL 
injection volume of a syringe (Hamilton Microliters; Switzerland). 
The pH meter (Orion 3 Star, Thermo-Scientific) was used to adjust 
the pH of the mobile phase. Amount of the marker compound 
present in the crude plant extract was determined through the 
calibration curve. Calibration curve constructed by the 
corresponding peak area of the gallic acid as standard was plotted 
against the concentration of standards by means of linear 
regression. The stock solution of a standard compound was 
prepared by dissolving the known amount of gallic acid in methanol 
at a concentration of 1 mg/ml.  
Quantification of gallic acid in M. esculenta extract 
M. esculenta extract was standardized by RP-HPLC under the 
isocratic conditions using the external standard calibration 
technique. A bioactive compound was identified by comparing with 
the respective retention time (Rt) of the gallic acid as standard. The 
calibration curve was plotted by plotting peak areas against 
concentrations and five standard marker ranges from 100–500 
μg/ml. The standard compound shows a good linearity between 
concentrations and the peak area, with the correlation coefficient 
(r2) of 0.998.  
Obtained chromatograms from HPLC analyses of the extract and 
their respective markers are shown in fig. 1. The optimum 
separation of was achieved by using the mobile system at the 
volume ratio of acetone with 1 % acetic acid in water in the ratio of 
74: 24 (v/v) with a flow rate of 1 ml/min. The retention time of gallic 
acid was found to be 4.013 min. The percentage amount of standard 




Chromatogram of gallic acid 
 
Chromatogram of M. esculenta extract 
Fig. 1: RP-HPLC chromatograms of gallic acid and M. esculenta extract 
 
Excipient compatibility test 
Excipient compatibility test was carried out for 21 d by taking the 
physical mixture in 1:5 ratio of CoQ10 separately with PATO, OA and 
P407 respectively at temperature 40±2 °C and relative humidity 75±5%.  
Experimental design of NLCs 
In this study, 23 factorial design was used to optimize NLCs. In order 
to optimize, the amount of solid lipid, (PATO, X1), amount of liquid 
lipid (OA, X2) and concentration of surfactant (P407, X3) were 
selected as independent variables. Each factor was set at two 
levels+1 and-1. The actual values and coded values of different 
variables are given in table 1. Eight formulations of NLCs (F1-F8) 
were prepared according to design. The particle size and % 
entrapment efficiency were taken as response parameters. 
Evaluation of response parameters of NLC 
Particle size and zeta potential 
The particle size and the zeta potential of the formulations were 
measured using Malvern Zetasizer. The polydispersity index (PDI) 
was used as a parameter of the size distribution. The samples were 
diluted with double distilled water prior to particle size and zeta 
potential determination at 25 °C. 
Entrapment efficiency 
The percent entrapment efficiency of the CoQ10-ME loaded NLC was 
calculated by using the equation reported by Shah and Pathak, 2010 
[13] and %EE was calculated by the following equation:  
%EE	  	 Wa	WsWp/Wa	 
Where Wa is the amount of drug added in the system, Ws is the 
amount of drug in the supernatant after centrifugation, and Wp is 
the amount of drug in the purification medium. 
Drug content determination by HPLC 
Estimation of gallic acid (GA) content in the formulations was 
analyzed by HPLC. (The standard stock solution was prepared by 
dissolving the known amount of GA in methanol to get a 
concentration of 1000 μg/ml. Different aliquots were prepared by 
subsequent dilution with the same solvent. Samples were stored at 4 
°C and protected from light before using. In this analysis, the mobile 
phase of acetonitrile and deionized water was used as a proportion 
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of 35:65, 30:70 and 25:75 v/v (1% glacial acetic acid; pH 2.2) which 
were sonicated for 15 min and degassed prior to use. Before 
applying all samples were also filtered through 0.45 μm (NYL) 
syringe filter. The recoveries of standard compounds from various 
samples and formulation at three concentration levels were 
determined by measuring the percentages of detecting 
concentrations over additional concentrations. The quantitative 
analysis was repeated about three times (n= 3) by comparing and 
interpolating the peak area (response) of the sample with the 
standard. 
 
Table 1: Formulation of NLC of Q10-ME using 23 factorial design 
Formulation 
code 
Amount of CoQ10 and plant extract 
(1:1)  








F1 10 -1 -1 -1 Particle size 
percentage 
entrapment efficiency 
F2 10 +1 -1 -1 
F3 10 -1 +1 -1 
F4 10 -1 -1 +1 
F5 10 +1 +1 -1 
F6 10 +1 -1 +1 
F7 10 -1 +1 +1 
F8 10 +1 +1 +1 
F9 10 -0.098 -0.834 +0.187 
Where: X1:-1= 0.5% and+1= 2.5% w/w: X2:-1= 0.10% and+1= 0.30% w/w: X3:-1= 0.80% and+1= 1.2% w/v 
 
Statistical analysis 
The effect of independent variables on the responses was modeled by 
Design Expert software version 11 (Stat-Ease, Inc., Minneapolis, USA). 
Polynomial equations were generated for the dependent variables that 
were reduced by removing non-significant coefficients by applying one 
way ANOVA. Level of significance was set at p<0.05 [14]. 
Validation of experimental design 
The experimental design was validated by an extra checkpoint 
formulation (F9) [15]. The predicted values for particle size and 
entrapment efficiency for F9, generated by their respective 
polynomial equations were compared with experimental values and 
tested for statistical significance using pooled t-test at 95% 
confidence interval, and degree of freedom = 3 (p<0.05) [16].  
Selection of the optimized formulation 
Optimized formulation was selected on the basis of the desirability 
factor as calculated by the Design Expert software version 11 (Stat-
Ease, Inc., Minneapolis, USA). 
Visualization by transmission electron microscopy 
The morphology of selected CoQ10 ME loaded NLC dispersion was 
observed by transmission electron microscopy. One drop of the 
CoQ10 ME loaded NLC dispersion was spread on a carbon-coated 
copper grid and the excess droplets were removed with filter paper. 
A drop of 4%w/v phosphotungstic acid solution was dropped into 
the grid. The negatively stained sample was air dried at room 
temperature and examined at 15000X magnification.  
Stability studies 
Stability of the selected optimized NLCs dispersion was determined 
as per ICH guidelines for 28days Effects of temperature and relative 
humidity on physical changes, particle size, and drug content was 
studied for NLC dispersion [17]. 
RESULTS 
Drug-excipient compatibility 
Drug-excipient compatibility was determined by the binary mixture 
method. After 21 d no physical change was observed. The drug content 
was found out to be 97.25, 96.46 and 98.62 % for physical mixture PATO, 
OA and P407 respectively. Thus it could be said that the excipients 
selected for the formulation are safe and have no impact on the efficacy 
of the product. Furthermore, it is supported with the help of interaction 
plots obtained by the statistical design (23 factorial design). 
23 Factorial design 
The factorial design was used for optimization of CoQ10-ME loaded 
NLC as it is an effective tool for optimization of independent 
variables. Thus, formulation F1-F8 were prepared according to the 
factorial design and evaluated for the dependent variables. 
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Fig. 3: Response surface plot for analysis entrapment efficiency 
 
Preparation of nanostructured lipid carriers 
NLCs were prepared by solvent injection technique that is based on 
rapid diffusion of the solvent across the solvent-lipid interface with 
the aqueous phase [18]. Thus, the diffusion rate of the organic 
solvent through the interface seems to be a critical parameter for the 
particle size determination. The major limitation with NLCs is its 
separation due to their small size and low density of the lipids. To 
overcome this limitation, in the present study, the pH of the 
dispersion was reduced to 1.5–2 to adjust the zeta potential for 
aggregation of NLCs and facilitate the centrifugation and 
consequently separation. 
Particle size and zeta potential measurements 
Values of the particle size and surface charge of the developed NLCs 
are shown in table 2. The results showed that the amounts of PATO 
and OA were critical parameters governing the particle size. After 
production, the mean diameters of the particles were in the range of 
165.9 ~226.8 nm, depending on the lipid loading, and polydispersity 
was<0.45. Upon increasing the OA percentage in the lipid matrix 
from 0.10% to 0.30% w/w, the mean particle size decreased. F5 
exhibited the smallest size among all the formulations tested. As 
depicted in table 2, the zeta potential value of the lipid nanoparticles 
was negative.  
Drug entrapment efficiency 
An important issue with respect to the use of nanoparticles as drug 
carriers is their capacity for drug loading. The effects of OA 
concentration on drug entrapment efficiency of NLC were investigated. 
It is clear that the drug entrapment efficiency of nanoparticles 
increased from 80.63 to 94.50% respectively, with increasing the 
percentage of OA from 0.1 to 0.3 % by weight (table 2). 
  
Table 2: Physical characterization of CoQ10-ME NLCs 
Formulation code Particle size (nm) PDIa Zeta potentiala (mV) %EEa 
F1 176.52±0.12 0.243±0.09 -30.01±0.31 80.61±0.62 
F2 214.18±0.31 0.261±0.21 -31.39±0.52 85.58±0.43 
F3 288.57±0.65 0.263±0.10 -30.02±0.46 62.55±0.49 
F4 264.58±017 0.267±0.74 -28.08±0.17 79.64±0.22 
F5 169.46±0.58 0.212±0.17 -36.39±0.08 90.06±0.17 
F6 197.27±0.09 0.249±0.45 -31.89±0.24 86.45±0.36 
F7 254.2±0.16 0.243±0.76 -33.45±0.78 83.97±0.41 
F8 534.5±0.27 0.384±0.08 -28.51±0.09 87.43±0.35 
F9(P) 226.25±0.10 0.267±0.14 -31.28±0.11 82.641±0.52 
F9(E) 226.11±0.29  0.258±0.35 -31.35±0.34  82.55±0.41 
P= Predicted, E= Estimated, a= mean±SD, n = 3. 
 
Statistical analysis 
Statistical analysis was done by Design expert software version 11 
(Stat-Ease, Inc., Minneapolis, USA) and the second order polynomial 
equations were derived. The transformed equations are, 
Particle	size  	264.41 16.41X1 49.27X2 50.23X3
 23.86X1X2 36.81X1X3 32.44X2X3
 63.05X1X2X3 
Percentage	drug	entrapment
 	82.04 5.34X1–1.03X2 2.34X3
 2.40X1X2–2.78X2X3  2.36X1X3	
 	3.24X1X2X3 
Where X1, X2, and X3 are the independent variables. The effects of 
various independent variables on the dependent variables are 
illustrated in fig. 2 and fig. 3 that clearly depicts the effect of varying 
the levels of independent factors on dependent factors. 
These polynomial equations were utilized for validation of the 
experimental design. An extra design checkpoint formulation (F9) was 
prepared. Calculation of the predicted value(s) for particle size and % 
EE were made and compared with the experimental values as 
determined by evaluating F9. Close resemblance between predicted 
and experimental values indicated the validity of the generated model. 
Assessment of interaction in independent variables 
The possible excipient interaction was analyzed with the help of 
graphs obtained by the statistical design, for each response 
parameter(s), which in turn indicates the significance of 
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Fig. 4: Interaction between independent factors and particle size 
 
 
Fig. 5: Interaction between independent factors and entrapment efficiency 
 
Validation of the experimental design 
An extra design checkpoint formulation (F9) was made and the 
predicted value and experimental values of dependent variables 
were compared using pooled t-test at 95% confidence interval, a 
degree of freedom 3 and p<0.05. No significant difference was 
recorded between the two values (table 2) thereby establishing the 
validity of the generated model. 
Selection of optimized formulation 
Eventually, F9 with desirability factor = 1, the particle size of 226.11 
nm and entrapment efficiency of 82.55±0.41%, was identified as the 
optimized formulation.  
Transmission electron microscopy 
Transmission electron microscopic image of NLC indicated spherically 
shaped particles with narrow size distribution. No aggregation was 
observed as shown in fig. 3.8. As viewed, all the particles were less than 
200 nm, a size particularly suitable for topical delivery. 
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Stability studies 
Stability of the selected optimized NLCs dispersion was determined as 
per ICH guidelines on the basis of effects of temperature and relative 
humidity on physical changes, particle size, and drug content was 
studied for NLC dispersion. The drug content found out to be 98.16 %, 
95.49 and 93.38% on subjecting the formulation for 28 d at 25±2 °C 
temperature 60±5% RH, 30±2 °C temperature 65±5% RH and 40±2 °C 
temperature 75±5% RH respectively. At the end of the study, there 
was no any sign of physical change or deformity. 
DISCUSSION 
The results of the experimental design were analyzed using Design 
Expert software. The selected independent variables like the amount of 
PATO, amount of OA and concentration of P407 had significantly 
influenced the particle size and, % EE that is very much evident from the 
polynomial equations. The possible interactions between X1X2, X2X3, 
and X1X3 for each response were also investigated (fig. 4 and fig. 5).  
Graphically, the interactions are visualized by lack of parallelism in 
the lines, for each response parameter(s) indicated interactions. The 
response surface plots (fig. 2 and fig. 3) generated using polynomial 
equations represent a simultaneous effect of any two variables on 
response parameter taking one variable at a constant level. On 
carefully observing these plots, the qualitative effect of each variable 
on each response parameter can be visualized. 
The effect of each independent variable was observed on these 
dependent variables and the following conclusions were drawn  
In increasing the amount of PATO, the particle size increased, 
indicating that the particle size is highly dependent on the amount of 
lipid used. On increasing the lipid content the viscosity of the lipid-
solvent phase increase resulting in the reduction in the diffusion rate 
of the solute molecules to the outer phase that results in an increase 
in particle size. But as observed in table 2 the increase in particle 
size leveled at 2% w/w of PATO and on further increase in the 
amount of PATO, the particle size decreased.  
The abundance of lipid results in diffusion of lipid to the outer core 
of NLC resulting in a decrease in particle size. In addition to particle 
size, the lipid content also affected the entrapment efficiency. An 
increase in the amount of PATO resulted in an increase in % EE 
increase, higher Precirol content means availability of more amounts 
of the triglycerides containing a binary mixture of tripalmitin and 
tristearin, act as solubilizing agents for the lipophilic drug(s) [19]. 
Careful analysis of the experimental design revealed that the liquid 
lipid, oleic acid as another major component that affected the 
particle size of NLCs. As indicated by factorial design, the particle 
size decreased while moving from lower level to higher level of OA. 
Thus when the amount of OA increased from–1 level to+1 level, the 
particle size decreased from 534.5 nm to 169.46 nm. 
The third independent variable, P407 was also varied at different 
levels using factorial design and its effect on particle size was 
analyzed. At the lowest level, the particle size was 214.18 nm 
(formulation F2) that dropped to 197.27 nm (formulation F6) at the 
highest level of P407 indicating that increase in the amount of 
poloxamer can cause a decrease in particle size.  
Increase in P407 causes a surfactant induced reduction in surface 
tension and prevents aggregation of the particles consequently 
leading to a decrease in particle size. Similarly, the percent 
entrapment efficiency was observed to decrease from 90.06±0.171 
% to 87.43±0.359% as we moved from–1 to+1 level of surfactants. 
According to our criteria of lower particle size, higher % EE, and higher 
desirability factor, F9 was selected as optimized formulation (desirability 
value of 1.0). Consequently, the coded optimized level for the amount of 
PATO, amount of OA, the concentration of P407, were identified as 
−0.098,-0.834, and+0.187, respectively. These coded optimized values 
can be converted to actual optimized values by using principles of 
transformation by use of the following equation [20]. 
Coded Value (x) = Actual value of X– Average of the actual level/
/0.5difference between the actual level 
Transmission electron microscopic image of optimized NLC 
indicated spherically shaped particles with narrow size distribution. 
No aggregation was observed as shown in fig. 6.  
CONCLUSION 
Nanostructured lipid carrier of Coenzyme Q10 and M. esculenta leaves 
extract were successfully developed and statistically optimized by 
using 23 factorial design. The obtained NLCs were nanosized 
particles with high entrapment efficiency. The enhanced permeation 
of the drug through NLC carriers might help in enhancing the 
pharmacological efficacy of CoQ10, subsequently enhancing the anti-
aging potential of CoQ10 with polyphenolic herbal extract of M. 
esculenta leaves. The statistically optimized CoQ10-ME NLC carriers 
containing GA may prove the prominent and enhanced antiaging 
potential of CoQ10. 
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